Form 8-K - Current report:
SEC Accession No. 0001193125-25-004052
Filing Date
2025-01-10
Accepted
2025-01-10 06:46:01
Documents
14
Period of Report
2025-01-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d910174d8k.htm   iXBRL 8-K 24948
2 EX-99.1 d910174dex991.htm EX-99.1 4051
  Complete submission text file 0001193125-25-004052.txt   153383

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20250108.xsd EX-101.SCH 2895
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20250108_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20250108_pre.xml EX-101.PRE 11291
16 EXTRACTED XBRL INSTANCE DOCUMENT d910174d8k_htm.xml XML 3615
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 25520296
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)